Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
17 mai 2022 08h01 HE | Phathom Pharmaceuticals
New investigational data evaluating vonoprazan in erosive esophagitis (EE) Research highlights real-world evidence of unmet needs that exists for the treatment of Helicobacter pylori (H. pylori)...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
10 mai 2022 08h00 HE | Phathom Pharmaceuticals
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H....
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
04 mai 2022 08h01 HE | Phathom Pharmaceuticals
Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE)Provides capital for launch of vonoprazan in H. pylori...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
01 avr. 2022 08h01 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
researchdrivelogo.jpg
Global Digital therapeutics Market to Perceive Noteworthy Growth Due to Growing Cases of Chronic Disorders Worldwide [175-Pages] | Divulge by Research Dive
21 mars 2022 09h03 HE | Research Dive
New York, USA, March 21, 2022 (GLOBE NEWSWIRE) -- A new report on the global digital therapeutics market has been added by Research Dive to its repository. As per the report, the market is expected...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
14 mars 2022 08h02 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 14, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress
01 mars 2022 16h04 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)
09 févr. 2022 16h04 HE | Phathom Pharmaceuticals
Vonoprazan met the primary endpoint for all three dose levels (10 mg, 20 mg, 40 mg) taken on-demand, demonstrating faster and sustained relief of episodic heartburn as compared to placebo...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
08 nov. 2021 08h00 HE | Phathom Pharmaceuticals
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May...
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting
21 oct. 2021 08h00 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...